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Abstract 
The use of non-opioid analgesics following surgery has proven beneficial in managing pain and 
decreasing adverse outcomes following surgery. Data assessing outcomes related to opioid use is 
limited in kidney transplant recipients (KTRs). We evaluated the effectiveness of implementing a 
reduced to no opioid use protocol in KTRs. This retrospective cohort study included adult KTRs 
between January 2017 and July 2019 with a multimodal analgesic protocol (MAP), focused on 
limiting opioids, implemented in August 2018. We compared analgesic requirements in 
morphine milligram equivalents (MME) during transplant admissions between the MAP cohort 
and traditional cohort. There were 217 KTRs who met criteria. Inpatient opioid use was 
significantly reduced in the MAP cohort (16.5 + 19.2 MME/day vs 24.7 + 19.7 MME/day; p 
<0.05) with no significant difference in pain scores. No use of opioids within six months of 
discharge was significantly increased in the MAP cohort (50% vs 7%; p <0.001) and there were 
no reported deaths at six months in either cohort. The use of multimodal analgesia is beneficial 
in KTRs to provide adequate pain control with limited to no exposure of opioids during 
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Introduction 
Many common surgeries and diseases are associated with an increased risk of chronic opioid use,  
including patients with kidney failure who may experience pain that is multifactorial in nature or 
related to concomitant comorbidities.1 3 Inadequate pain control has been associated with 
prolonged hospital length of stay (LOS), increased readmission secondary to pain, and decreased 
quality of life.1 One promising strategy for reducing opioid use in the operative setting is the use 
of multimodal analgesia extrapolated from an enhanced recovery after surgery pathway (ERAS). 
The ERAS pathways utilize multimodal analgesia and focus on a set of protocols implemented 
before, during, and after surgery to ensure optimal outcomes. The intended outcomes include 
reduction or elimination of opioid use postoperatively or at discharge. Compared with traditional 
management, multimodal analgesia can reduce opioid use, in the immediate and long term post-
surgical periods.4 To date, there is minimal data published on minimizing and reducing opioid 
use postoperatively in this surgical transplant population.  
 
Existing literature has elucidated the negative effects of opioids in the transplant population. The 
use of pre-surgical opioid analgesics has been increasingly recognized as a predictor of post-
operative complications and resource utilization in a variety of surgical populations, including 
general, orthopedic, and liver transplant surgeries.5 7 Opioid use prior to kidney transplantation 
was strongly associated with inferior one-year post-transplant outcomes. High-level opioid use, 
defined as > 1,000 morphine milligram equivalents (MME) per year, predicted a 46% increased 
risk of death and 28% increased risk of all-cause graft failure.8 A similar retrospective study 
assessing chronic opioid use prior to transplant found an increased mortality risk noting that 
additional studies are warranted to understand the mechanisms.9 Comparably, opioid use post-
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transplantation showed similar trends of opioid use prior to transplant. Recipients with increased 
postoperative opioid requirements exhibit increased risk of death and graft failure in the first year 
after transplant.2 Effects of high-level opioid use in the first year after transplant, predicted twice 
the risk of death and 68% higher all-cause graft failure over the subsequent year, with an 
increased risk persisting over five years compared to no use.8 These outcomes further exemplify 
the need to implement opioid limiting regimens in KTRs. 
 
Multimodal Analgesia 
Multimodal analgesic agents, such as ketamine, gabapentinoids, and tramadol, have been 
evaluated and supported in the literature for perioperative and postoperative use in a variety of 
surgical patients. Ketamine is an N-methyl-d-aspartate (NMDA) receptor antagonist that has 
been used in the setting of chronic, cancer, neuropathic, and postsurgical pain due to the NMDA 
receptor blockade that results in decreased nociceptive and inflammatory pain transmission.10 A 
large systematic review including 130 studies with 8341 patients evaluated the efficacy and 
safety of perioperative intravenous ketamine in adult patients undergoing various surgical 
procedures. The study found perioperative intravenous ketamine reduced postoperative opioid 
consumption over 24 hours by 8 MME and over 28 hours by 13 MME, when compared to 
placebo. Additionally, perioperative intravenous ketamine reduced pain at rest at 24 hours by 
5/100 mm on visual analogue scale and at 48 hours by 5/100 mm. Results were consistent when 
analyzed by pain at rest or on movement, operation type, and timing of administration, or 
sensitivity to study size and pain intensity. In regards to safety, ketamine bolus doses of 0.25-1 
mg/kg and infusions 2-5 µg/kg/minute produced no increased risk of central nervous system side 
effects when compared to placebo.11   
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Although initially developed as an antiepileptic drug, gabapentin has analgesic properties 
h gh i  in e ac i n i h -2- -subunits of voltage-gated calcium channels, decreasing the 
release of excitatory neurotransmitters.12 Through a similar mechanism, pregabalin has also been 
evaluated for its reduction in perioperative opioid consumption and pain scores. Several meta 
analyses found that pregabalin leads to a significant reduction in pain scores and perioperative 
opioid consumption.13 15 
 
Tramadol is a synthetic analogue of the opioid drug codeine; however, the analgesic potency is 
found to be ten times less than morphine. Tramadol is considerably safer, as it is significantly 
less likely to cause respiratory depression and addiction when compared to other opioid 
analgesics.16 It produces analgesia through various pathways such as a weak mu-opioid receptor 
agonist or as a serotonin and norepinephrine reuptake inhibitor for nociception.17,18 Tramadol has 
significant benefit due to its dual mechanism of action and minimal side effect profile. As with 
all medications, patient specific factors and clinical judgement should play a role in appropriate 
analge ic managemen . F  he e  f hi  d , amad l a  n  c n ide ed an i id  
and was a key component of the multimodal analgesia regimen. 
 
The majority of research regarding pain management in kidney transplant patients has focused 
primarily on kidney transplant donors, with relatively little known about the postoperative 
analgesic management of KTRs. This study will address several outcomes that have not been 
collectively reviewed in previous studies. The aim of this study was to examine the pain 
management outcomes utilizing a Multimodal Analgesia Protocol (MAP) in KTRs. 
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Materials and Methods 
Study design  
This was a single-center, retrospective cohort study conducted at our institution between January 
2017 and July 2019 with the implementation of MAP (Figure 1) in August 2018. This protocol 
was standardized as all transplants were performed by the same group of surgeons. The 
traditional cohort, consisting of those transplanted prior to August 2018, was compared to the 
MAP cohort which was defined as those transplanted following the MAP implementation. The 
traditional cohort was discharged on as needed acetaminophen and oxycodone, regardless of 
their pain score at the time of discharge or their use of opioids prior to the transplant. The MAP 
cohort was discharged on acetaminophen, gabapentin, and tramadol. For the purposes of this 
study, tramadol was not conside ed an i id  al h gh e ackn ledge i  mechani m f 
ac i n a  being i id-like  and i  being c n ide ed a c n lled b ance. F ll -up was 
concluded at six months following discharge. This study was approved by the Institutional 
Review Board (protocol number 19-1408), which reviewed the ethical, scientific, and medical 
appropriateness of the study before commencement. 
 
Transplant Recipients 
Adults (> 18 years of age) who were recipients of a kidney transplant from a living or deceased 
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The primary study objective was to assess the opioid use during admission defined as the 
preoperative through postoperative periods, quantified in MME. Secondary efficacy endpoints 
included recipient reported pain severity scores (scale 0-10), LOS, amount of opioid use within 
six months prior to and following transplantation, 30-day readmission rates and 6-month patient 
survival. Secondary safety endpoints included intolerance or adverse drug events due to 
multimodal analgesia medications. 
 
Procedures 
In the traditional cohort, recipients received fentanyl intraoperatively, while postoperatively had 
intermittent intravenous fentanyl available on an as needed basis. For the traditional cohort, both 
post-operative agent, dose, and duration were subject to surgeon discretion. Recipients were 
discharged on oxycodone 5 mg orally every four to six hours as needed for moderate to severe 
pain in addition to acetaminophen 325 mg orally every four to six hours as needed for mild pain 
or fever.  
 
To minimize opioids, the MAP cohort recipients received preoperative, intraoperative and 
postoperative analgesia management as described below. 
Preoperative 
Multimodal analgesia of acetaminophen 1000 mg orally and pregabalin 50 mg orally were 
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A ketamine bolus 0.5 mg/kg was administered after induction of anesthesia, followed by a 0.25 
mg/kg/hr infusion. The surgical team performed a transversus abdominis plane (TAP) block with 
40 mL of 0.25% bupivacaine prior to abdominal closure. The goal during intraoperative pain 
management was to utilize multimodal analgesia to minimize intravenous opioid use. However, 
exceptions for chronic opioid users were considered, as deviations from MAP due to tolerance 
from previous chronic opioid use could occur. 
Postoperative 
Analgesia regimens were dependent on pain severity. Oral acetaminophen 1000 mg three times 
daily was given for a minimum of five days postoperatively and then transitioned to as needed 
dosing. Oral gabapentin 100 mg was initially administered daily with dose and frequency 
adjustments based on renal function for a duration of fourteen days. Oral tramadol 50 every six 
hours as needed for moderate pain or 100 mg every six hours for severe pain could be given. The 
total dose and frequency of tramadol was adjusted based on recipien  enal f nc i n. If 
tramadol was contraindicated, oral oxycodone 5 mg every six hours as needed for moderate pain 
and 10 mg every six hours as needed for severe pain were considered. Intravenous (IV) fentanyl 
50 mcg every six hours as needed for two doses was administered for severe pain with 
reassessment of pain when requiring more than two doses in a 24-hour period. If pain was not 
well controlled, fentanyl could be adjusted to 50-100 mcg IV every four hours as needed. 
Additionally, recipients who were on chronic opioids preoperatively were continued on their 
home pain medication regimen. 
Discharge 
Pain management included tramadol 50 mg orally every six hours as needed for moderate pain 
and 100 mg orally every six hours as needed for severe pain for five days; dose and frequency 
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were adjusted based on renal function. If tramadol was contraindicated, oxycodone orally 5-10 
mg every six hours as needed was prescribed. Oral gabapentin 100 mg daily for two weeks was 
prescribed based on renal function. Oral acetaminophen 1000 mg three times daily for five days 
was provided or as long as the recipient was taking tramadol or opioids. Recipients were asked to 
bring unused medication to follow up clinic visits. 
 
Data was obtained via chart review using the Epic Electronic Health Record System. Opioid use 
throughout admission was converted to MMEs and standardized by length of hospital stay. 
Opioid prescriptions within six months prior to admission and within six months following 
discharge were collected based on outpatient prescriptions that were recorded in the medical 
record. The sum of MME within those six months were categorized into MME levels (No use, 
Level 1: >0 to 150mg,  Level 2: 151-300mg,  Level 3: 301-500mg, Level 4: >500mg).8 No use 
was defined as no opioid use at any time within the six-month time frame and tramadol was not 
evaluated as an opioid for this measurement. MME conversion factors were standardized using 
the Center for Disease Control and Prevention resource for analyzing prescription data.19 
Additionally, daily recipient reported pain scores were assessed using a numeric (0-10) pain 
rating scale and averaged based on hospital length of stay. KTRs who did not follow MAP were 
included in the MAP cohort and defined as those receiving opioids beyond postoperative day 
one, receiving opioids prior to admission, or were discharged with an opioid prescription.  
 
Statistical Analyses 
Parametric and nonparametric data are presented as means + standard deviation (SD) or median 
with interquartile range (IQR), respectively. For parametric continuous variables, we used the 
10 
UTILIZING MULTIMODAL ANALGESIA 
unpaired t test. Categorical variables were presented as frequencies and percentages. Chi-square 
test with Yates Correction or Fisher exact test as appropriate were used to analyze nominal and 
ca eg ical da a. M d  Median e  a  ed  c m a e median al e . T -tailed p-values 
<0.05 were considered statistically significant.  
 
Results 
Recipient disposition and demographics  
Between January 2017 and July 2019, 217 consecutive KTRs were analyzed. There were 147 
KTRs in the traditional cohort and 70 KTRs in the MAP cohort. There were no differences in 
recipient characteristics between the traditional and  MAP cohorts (Table 1). Nor were there 
differences between KTRs who followed the MAP and those who did not follow the MAP 
protocol (Table 2). 
 
Traditional vs MAP 
Endpoints are outlined in Table 3. The overall MME during admission was significantly reduced 
in the MAP cohort (mean 16.5; SD 19.7 MME/day) compared with the traditional cohort (mean 
24.7; SD 19.2 MME/day) (p<0.01). Opioid use in deceased donor KTRs in the MAP cohort 
(mean 14.5; SD 18.3 MME/Day) was significantly less compared to deceased donor KTRs in the 
traditional cohort (mean 25.5; SD 21.6 MME/Day) (p <0.01). There was no significant 
difference in overall MME between cohorts in KTRs of living donors.  
 
There was no significant difference in recipient reported pain scores between cohorts. Decreased 
length of stay was observed in recipients who followed the MAP (median 5, IQR 4-7 days) 
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compared to the traditional cohort (median 6, IQR 5-8 days), although not statistically 
significant. Opioid use within six months post discharge was significantly reduced in the MAP 
cohort for all but level 2 opioid use. Up to 50% of recipients in the MAP cohort did not have any 
outpatient opioid use within six months of discharge compared to only 7% in the traditional 
cohort (p<0.001). Of the traditional cohort, 25% had level 4 opioid use and 61% had level 3 
opioid use within the timeframe, while the MAP cohort significantly decreased to 9% (p<0.05) 
and 21% (p<0.001), respectively. The rate of readmission was significantly decreased in the 
MAP cohort (21% vs 38%; p<0.05) and time to readmission trended longer in the MAP cohort 
(mean 11.8, SD 10.5 days vs mean 8.5, SD 6.9 days) but was not significant. There were no 
deaths within six months of discharge in either cohort.  
 
Followed MAP vs Did Not Follow MAP 
Endpoints are outlined in Table 4. KTRs who followed the MAP (n=40) had significantly less 
opioid use throughout transplant admission (mean 7; SD 4.1 MME/day vs mean 29; SD 23.8 
MME/day) (p<0.01) than KTRs who deviated from the protocol (n=30). Length of hospital stay 
was lower in KTRs who followed the MAP (median 5; IQR 4-7 days vs median 6.5; IQR 5-8) 
days) although it did not reach significance. There was no significant difference in recipient 
reported pain scores between these recipients. Of those who did not follow the protocol, 23% had 
an active opioid prescription within the six months leading up to transplant compared to 10% 
who followed the MAP protocol. Up to 60% of these recipients received oxycodone and 40% 
received intravenous opioids beyond postoperative day one. Despite not following the protocol, 
30% did not receive an opioid prescription upon discharge.  
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Safety Endpoints  
There was one adverse drug event due to gabapentin in the MAP cohort that included lip, throat, 
and facial swelling. There were no readmissions related to opioid use in the MAP cohort; 
however, two recipients in the traditional cohort were readmitted for nausea, vomiting, or 
constipation which resulted in the oxycodone being discontinued. 
 
Discussion 
By exposing the patient to less opioids during admission and at discharge, recipients not only had 
comparable pain scores that demonstrated adequate pain control but had significantly less 
opioids during the six-month period following transplant. Similarly in a previous cohort analysis 
of living kidney donors, the ERAS cohort utilizing a similar multimodal analgesic approach had 
a 40% reduction in morphine dose equivalents compared to the traditional cohort with similar 
pain scores.20 These findings align with previous results showing multimodal analgesia reduced 
opioid use in both the immediate and long term post-surgical periods.4 A cross-sectional 
comparative study comparing hemodialysis patients with deceased donor KTRs found that a 
successful kidney transplantation did not lead to a significant reduction in pain prevalence when 
compared to chronic hemodialysis patients and pain relief medication are underused in kidney 
transplant recipients. Therefore, it is essential to manage pain with non-opioid analgesics to 
reduce adverse and potentially fatal adverse effects of opioid analgesics.21 By following a no 
opioid to limited opioid MAP protocol at discharge, the MAP cohort had significantly less opioid 
use within six months following discharge. There was a significant increase in those who had 
N  e  or Level 1 use in the MAP cohort and a significant decrease in Level 3 or higher opioid 
use in the six-month period. Our study supports the use of multimodal analgesia to minimize or 
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eliminate opioid use in KTRs during transplant admission as adequate pain control and decreased 
outpatient opioid prescriptions can play a role in reducing the serious risks of adverse drug 
events due to opioids such as addiction, respiratory depression, and even death. 
 
It should be noted that the overall decrease in MME during admission appears to be driven by 
deceased donor KTRs. The difference between living and deceased donor recipients is 
multifactorial, but we can speculate a confounding factor could have been a more structured 
preoperative and postoperative medication regimen. Living donor recipients have scheduled 
an lan a i n ge ie  hich can all  ime  l e  he eci ien  MME or set a goal prior to 
the procedure. Contrasting, deceased donor recipients can wait several years before a kidney is 
immediately available, which makes managing preoperative opioid levels challenging. 
Additionally, deceased donor kidneys may require continued dialysis which can precipitate 
uremia and edema, contributing towards he eci ien  pain. Further research is needed to 
elucidate this difference. However, we continue to see the beneficial effects multimodal 
analgesia has compared to standard opioid pain management that previously included 
intraoperative fentanyl with a continued opioid infusion postoperatively.  
 
MAP Deviation 
Patients were included in this study regardless of preoperative opioid use to provide insight into 
managing patients with multimodal analgesics that may have varying levels of opioid 
dependence. Of note, 23% of those who deviated from the protocol had an outpatient opioid 
prescription upon admission, suggesting either pre-existing chronic use or opioid tolerance. The 
use of opioids beyond postoperative day one, whether oral oxycodone or IV opioids, appeared to 
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result in a continuation of opioids at discharge. Despite failing the protocol, 30% of recipients 
that received opioids beyond postoperative day one was not discharged with an opioid 
prescription.  
 
 A study exploring the metrics that influence transplant related costs found increased length of 
stay resulted in an increase in transplant related costs by US $3,422 per additional day.22 KTRs 
who did not deviate from the protocol had a decreased length of stay by approximately one day; 
although not statistically significant, we believe this to be clinically and financially significant. 
The rate of readmissions was also significantly reduced which could suggest better postoperative 
pain management with multimodal analgesia, however, this is only an association as we 
acknowledge several other confounding factors can contribute to readmission. We cannot neglect 
the concerns that dialysis patients and recent kidney transplant recipients are at a greater risk of 
opioid-related toxicities due to altered drug protein binding, metabolism, and excretion that can 
lead to accumulation of these opioids and potentially toxic metabolites.23 26 Additionally, opioid 
use may be related to riskier behaviors such as non-adherence to medications or follow-up 
appointments which may contribute to adverse post-transplant events.27  
 
Multimodal Analgesia 
 Multimodal analgesia methods are utilized in all phases of surgery to provide optimal pain 
control and accelerate recovery. The TAP block performed intraoperatively provides analgesia 
during surgery and for a short period following surgery and has been beneficial in managing pain 
for diverse surgical populations.28 30 There were no complications related to the TAP block and 
this is routinely performed for multiple procedures within our institution.  
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Intravenous ketamine is frequently used intraoperatively in a variety of surgical populations 
since it has been shown to reduce postoperative opioid consumption and decrease pain 
independent of operation type or timing administration without an increased risk for central 
nervous system side effects.11 In the postoperative setting, fentanyl is a rapidly titratable, short 
acting opioid that was used on an as needed basis for patients with severe breakthrough pain that 
was not adequately treated with the multimodal analgesia regimen in place. Ketamine was not 
chosen to fulfill this role postoperatively due to the need for continuous infusion and requirement 
for a pain consultation. Therefore, fentanyl in the immediate postoperative setting allows for 
zero-use or some use up to 24 hours postoperatively. 
 
Amongst the gabapentinoids, pregabalin was selected for preoperative pain management due to 
its predictable pharmacokinetic profile in comparison to gabapentin and because its oral 
absorption is both extensive and proportional to dose.13 On the other hand, gabapentin was 
selected postoperatively due to its lower cost and easier access for patients. For some patients, 
pregabalin may require a prior insurance authorization or be more costly in the outpatient setting.  
 
Although tramadol is opioid-like and interacts with similar receptors as opioids, it has a safer 
side effect profile and lower addiction potential.16,17 In the MAP, tramadol is prescribed with a 
five-day supply on an as needed basis to adequately treat postoperative associated pain. Although 
it may be a limitation to not include MME associated with tramadol, our ultimate goal is not to 
be opioid free but to provide safe care to our patients while providing adequate analgesia. 
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The medical team works closely with psychology, social work, pain clinics, and patients to guide 
the patient into a good MME threshold prior to transplant. Tools and resources within the MAP, 
such as the pain coping workbook and transplant psychology, are valuable in aiming to reduce 
postoperative opioid consumption.  
 
The various modalities utilized in the MAP are not new to medical practice; however, when they 
are structured in a patient specific care pathway, positive results regarding pain control are 
achieved. By assessing the postoperative analgesic requirements following kidney 
transplantation, we are able to evaluate the impact of multimodal analgesia compared to the 
previous standard of treatment that utilized opioids freely, thus reducing negative downstream 
health outcomes. This study, in particular, provides valuable information on KTRs, who are 
eager to return to their daily routine without impairment due to pain. 
 
We address the limited number of studies focused on opioid use in KTRs, specifically the impact 
of pain on transplant outcomes. Although a previous report from the United Kingdom evaluated 
similar outcomes of hospital LOS and associated costs, the morphine patient-controlled analgesia 
postoperatively does not align with the current MAP used by our institution. To our knowledge, 
we are one of the first to execute this study at a large academic medical center within the United 
States. This study helps elucidate best practices for the unique kidney transplant population and 
allows clinicians to effectively guide analgesic therapy for specific populations within KTRs. 
Implementing this protocol within our institution was not without its challenges. The biggest 
barrier was organizing meetings with all of the stakeholders to create the protocol and order set. 
Once the protocol was finalized, educating the medical team on the protocol and addressing 
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which pain regimen to initiate following the surgical procedure was another challenge. There are 
still deviations when providers place orders outside of the order set and initiate a KTR on 
oxycodone without consulting the protocol. Another continued barrier specific to KTRs is that 
tramadol and gabapentin are renally dose adjusted, limiting the amount of medication that can be 
given for breakthrough pain when abiding by the recommended maximum dose. Pa ien  
perceived dependence of opioids at discharge was another barrier, however this was reduced 
through patient education. 
 
Limitations 
Some limitations include the retrospective nature of this study and potential for confounding 
factors and biases. The use of historical data as our data collection is reliant on accurate 
documentation and charting in the medical records. Pain severity scores documented within the 
records are subjective measurements and can vary between recipients. The opioid prescriptions 
collected are limited to those sent via our electronic health record and fill histories were unable 
to be disclosed by the statewide prescription drug monitoring program. Therefore, external 
prescriptions could not be captured. Our focus on minimizing opioid use in the perioperative and 
postoperative periods aims to discharge KTRs without opioids or the need to prescribe them in 
the outpatient setting due to effective multimodal analgesia management. However, the 
difference in opioid use within the six months following discharge could be attributed to 
increased awareness surrounding opioid prescribing and alternative prescribing patterns. Our 
findings assessed the change in prescribing habits as providers transitioned from prescribing 
oxycodone at discharge to tramadol. By reducing or avoiding the use of oxycodone at discharge, 
we aim to decrease unnecessarily prolonged narcotic use. Our goal is to provide safe medications 
18 
UTILIZING MULTIMODAL ANALGESIA 
to our KTRs and although tramadol interacts with the same receptors as opioids, it has a safer 
side effect profile when compared to traditional opioids (i.e., oxycodone, hydromorphone).17 We 
only captured readmissions to our institution, and thus could not include admissions to external 
facilities. Additionally, recipient comorbidities could potentially confound results, as 
complications associated with certain disease states can lengthen hospital stay or contribute to 
readmissions post-transplantation.31 34 Nonetheless, the results contribute to the limited literature 
on the pain management for KTRs and aid in improving the current standard of care and 
prevention of adverse drug reactions. 
 
In conclusion, this retrospective analysis of patients undergoing kidney transplantation, which 
focuses on the use of multimodal analgesia, shows promising results in decreased opioid 
consumption with similar pain scores, associated decrease in length of stay, and reduced 
readmissions. The data gathered from this study has the potential to improve current practice 
during transplant admission in the kidney transplant population. Additional studies that capture 
outpatient opioid use are warranted to provide further insight into transplant outcomes associated 
with use prior to or following transplantation. Future studies may focus on methods to prevent 
deviation from the MAP so recipients can benefit from positive outcomes associated with 
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Table 1: Baseline Characteristics for Traditional vs MAP Cohorts 
 




Age at Transplant, years 49.7 +  13.3  52.1 + 11.3  0.21 
Male 82 (56) 40 (57) 0.96 
Race    
Caucasian 65 (44) 29 (41) 0.81 
African American 72 (49) 32 (46) 0.76 
Other 10 (7) 9 (13) 0.22 
Employment    
Working 60 (41) 29 (41) 0.93 
Comorbidities    
HTN 121 (82) 59 (84) 0.87 
DM 51 (35) 22 (31) 0.75 
CAD 21 (14) 9 (13) 0.94 
CVD 11 (7) 6 (9) 0.99 
Other 27 (18) 11 (16) 0.77 
Mean Number  1.8 + 0.9  1.7 + 1  0.63 
Dialysis 129 (88) 62 (89) 0.86 
Native Kidney Primary Diagnosis    
HTN Nephrosclerosis 33 (22) 16 (23) 0.95 
DM 28 (19) 19 (27) 0.24 
IgA Nephropathy 11 (7) 2 (3) 0.3 
FSGS 18 (12) 4 (6) 0.21 
PKD 9 (6) 7 (10) 0.46 
Other 48 (33) 22 (31) 0.98 
Donor Type    
Deceased 101 (69) 45 (64) 0.62 
Pre-Admission Opioids within 6 
Months, MME    
No Use 137 (93) 59 (84) 0.07 
Level 1: >0 to 150mg 2 (1) 5 (7) 0.07 
Level 2: 151-300mg 1 (1) 2 (3) 0.51 
Level 3: 301-500mg 4 (3) 1 (2) 0.91 
Level 4: >500mg 3 (2) 3 (4) 0.62 
CAD, coronary artery disease; CVD, cerebrovascular disease; DM, diabetes mellitus; FSGS, focal segmental glomerulosclerosis; HTN, 
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Table 2: Baseline Characteristics for Followed MAP vs Did Not Follow MAP 
 
Characteristic N(%) or Mean + SD  Followed MAP  
(n=40) 
Did Not Follow 
MAP (n=30) 
p-value 
Age at transplant, years 53.2 + 10.7  51.9 + 11.4  0.63 
Male 24 (60) 16 (53) 0.75 
Race    
Caucasian 13 (33) 16 (53) 0.13 
African American 20 (50) 12 (40) 0.56 
Other 7 (18) 2 (7) 0.33 
Employment    
Working 17 (43) 12 (40) 0.83 
Insurance    
Medicare 20 (50) 9 (30) 0.15 
Medicaid 2 (5) 2 (7) 0.77 
Private 9 (23) 9 (30) 0.66 
Other 9 (23) 10 (33) 0.46 
Comorbidities    
HTN 36 (90) 23 (77) 0.24 
DM 14 (35) 8 (27) 0.63 
CAD 2 (5) 7 (23) 0.06 
CVD 3 (8) 3 (10) 0.71 
Other 3 (8) 8 (27) 0.06 
Mean Number  1.6 + 0.7  2 + 1.3  0.1 
Dialysis 36 (90) 26 (87) 0.96 
Native Kidney Primary Diagnosis    
HTN Nephrosclerosis 9 (23) 7 (23) 0.93 
DM 12 (30) 7 (23) 0.73 
IgA Nephropathy 1 (3) 1 (3) 0.84 
FSGS 2 (5) 2 (7) 0.77 
PKD 4 (5) 3 (10) 1.0 
Other 12 (30) 10 (33) 0.97 
Donor Type    
Deceased 27 (68) 18 (60) 0.69 
Pre-Admission Opioids within 6 
Months, MME 
   
No Use 36 (90) 23 (77) 0.24 
Level 1: >0 to 150mg 2 (5) 3 (10) 0.74 
Level 2: 151-300mg 1 (2.5) 1 (3) 0.84 
Level 3: 301-500mg 0 (0) 1 (3) 0.88 
Level 4: >500mg 1 (2.5) 2 (7) 0.80 
CAD, coronary artery disease; CVD, cerebrovascular disease; DM, diabetes mellitus; FSGS, focal segmental glomerulosclerosis; HTN, 
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Table 3: Endpoints for Traditional vs MAP 
 







MME/Day 24.7 + 19.7  16.5 + 19.2  <0.01 
Living 22.9 + 15  20 + 20.6  0.51 
Deceased 25.5 + 21.6  14.5 + 18.3  <0.01 
LOS, Days 6 (5-8)  5.5 (5-7)  0.55 
Living 5 (4-7)  5 (4-6)  0.96 
Deceased 6 (5-8)  6 (5-7)  0.23 
Pain Score 1.7 + 1.4  2 + 1.4  0.2 
Post-Discharge Opioid Use 
within 6 Months, MME 
   
No Use 10 (7) 35 (50) <0.001 
Level 1: >0 To 150mg 1 (0.6) 9 (13) <0.001 
Level 2: 151-300mg 10 (7) 5 (7) 0.93 
Level 3: 301-500mg 89 (61) 15 (21) <0.001 
Level 4: >500mg 37 (25) 6 (9) <0.01 
Readmissions, days 56 (38) 15 (21) <0.05 
Time to Readmission 8.5 + 6.9  11.8 + 10.5  0.12 
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Table 4: Endpoints for Followed MAP vs Did Not Follow MAP 
 




Did Not Follow MAP 
(n=30) 
p-value 
MME/Day 7 + 4.1  29 + 23.8  <0.001 
Living 8.1 + 4  33.1 + 23.3  <0.001 
Deceased 6.5 + 4.1  26.3 + 24.4  <0.001 
LOS, days 5 (4-7)  6.5 (5-8)  0.23 
Living 4 (4-5) 5 (4-10.5)  0.41 
Deceased 6 (4-7)  7 (5.3-7.8)  0.14 
Pain Score Average 1.8 + 1.2 2.3 + 1.6  0.14 
Post-Discharge Opioid Use 
within 6 Months, MME 
   
No use 28 (70) 7 (23) <0.001 
Level 1: >0 to 150mg 8 (20) 1 (3) 0.09 
Level 2: 151-300mg 2 (5) 3 (10) 0.74 
Level 3: 301-500mg 2 (5) 13 (43) <0.001 
Level 4: >500mg 0 (0) 6 (20) <0.05 
Readmissions, days 8 (20) 7 (23) 0.97 
Time to Readmission 11.5 + 11  12.1 + 22  0.95 
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Figure 1: MAP of Analgesia Methods 
 
Figure 1: The MAP involved multimodal analgesia medication implementation in the 
preoperative, intraoperative, postoperative, and discharge segments of care in accordance with 









Acetaminophen 1000 mg PO 
+ 
Pregabalin 50 mg PO 
+  




Ketamine bolus 0.5 mg/kg 
administered after induction 
and 0.25 mg/kg/hr infusion 
+ 
TAP block performed with 40 
mL 0.25% bupivacaine prior 
to closure 
 
Gabapentin initially at 100 mg PO 
daily X 14 days* 
+ 
Acetaminophen 1000 mg PO TID 
for minimum of 5 days 
postoperatively then as needed 
+ 
Fentanyl 50-100 mcg IV every 4-6 
hours as needed X 2 doses with 
reassessment if requiring > 2 doses 
in 24 hours 
+ 
Tramadol 50-100 mg PO every 6 
hours as needed* 
Contraindication to tramadol? 
If contraindicated, oxycodone 5-10 mg 
PO every 6 hours as needed 
Gabapentin continued at 100 mg 
PO daily X 14 days* 
+ 
Acetaminophen 1000 mg PO TID 
X 5 days or as long as patient is 
taking tramadol or opioids 
+ 
Tramadol 50-100 mg PO every 6 
hours as needed X 5 days* 
IV, intravenously 
PO, by mouth 
TID, three times daily 
TAP, transversus abdominis plane 
*Dose and frequency based on renal function 
If contraindicated, oxycodone 5-10 mg 
PO every 6 hours as needed 
Preoperative Intraoperative Postoperative Discharge 
Contraindication to tramadol? 
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